Success and failure of vaccines against renin-angiotensin system components

被引:31
作者
Brown, Morris J. [1 ]
机构
[1] Univ Cambridge, Clin Pharmacol Unit, Cambridge CB2 2QQ, England
关键词
SPONTANEOUSLY HYPERTENSIVE-RATS; VIRUS-LIKE PARTICLES; PROSPECTIVELY-DESIGNED OVERVIEWS; MAJOR CARDIOVASCULAR EVENTS; PRESSURE-LOWERING REGIMENS; BLOOD-PRESSURE; CONVERTING-ENZYME; ACTIVE IMMUNIZATION; HIGH-RISK; DOUBLE-BLIND;
D O I
10.1038/nrcardio.2009.156
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Therapeutic vaccination pre-dated modern drugs as a possible strategy for treating hypertension. This approach is now being rediscovered, through use of modified angiotensins as immunogens together with carriers and adjuvants. Effective blockade of the renin-angiotensin system (RAS) with treatment twice a year might suit patients who dislike taking drugs on a daily basis and would also be an attractive option for those who have blood pressures in the prehypertensive range, if it can prevent hypertension itself from developing. Proof of concept with a vaccine whose efficacy is easy to measure will encourage development of further vaccines directed against targets such as aldosterone or other pathways where alternative treatments are scarce or absent. Two angiotensin-based vaccines are currently in development: PMD3117 comprises modified angiotensin I coupled to keyhole limpet hemocyanin, and Cyt006-AngQb is a conjugate of angiotensin II linked to virus particles. Early phase II studies in patients with hypertension demonstrated some efficacy, but the vaccines are not as effective as existing inhibitors of the RAS. Large studies now in progress will establish whether further modification of the immunogen or adjuvant is required to boost antibody titers.
引用
收藏
页码:639 / 647
页数:9
相关论文
共 55 条
[1]
Agodoa L, 2007, J HYPERTENS, V25, P951
[2]
*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
[3]
A vaccine for hypertension based on virus-like particles:: preclinical efficacy and phase I safety and immunogenicity [J].
Ambuehl, Patrice M. ;
Tissot, Alain C. ;
Fulurija, Alma ;
Maurer, Patrik ;
Nussberger, Juerg ;
Sabat, Robert ;
Nief, Vera ;
Schellekens, Charlotte ;
Sladko, Katja ;
Roubicek, Kirsten ;
Pfister, Thomas ;
Rettenbacher, Manfred ;
Volk, Hans-Dieter ;
Wagner, Frank ;
Mueller, Philipp ;
Jennings, Gary T. ;
Bachmann, Martin F. .
JOURNAL OF HYPERTENSION, 2007, 25 (01) :63-72
[4]
[Anonymous], 2009, MED NEWS TODAY
[5]
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[6]
Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay [J].
Belz, GG ;
Butzer, R ;
Kober, S ;
Mang, C ;
Mutschler, E .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (04) :367-373
[7]
Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects [J].
Brown, MJ ;
Coltart, J ;
Gunewardena, K ;
Ritter, JM ;
Auton, TR ;
Glover, JF .
CLINICAL SCIENCE, 2004, 107 (02) :167-173
[8]
Better blood pressure control: how to combine drugs [J].
Brown, MJ ;
Cruickshank, JK ;
Dominiczak, AF ;
MacGregor, GA ;
Poulter, NR ;
Russell, GI ;
Thom, S ;
Williams, B .
JOURNAL OF HUMAN HYPERTENSION, 2003, 17 (02) :81-86
[9]
Aliskiren [J].
Brown, Morris J. .
CIRCULATION, 2008, 118 (07) :773-784
[10]
Renin: friend or foe? [J].
Brown, Morris J. .
HEART, 2007, 93 (09) :1026-1033